摘要
目的探讨进展期卵巢癌细胞减灭术后在紫杉醇与顺铂联合化疗方案(TP)基础上腹腔热灌注重组人血管内皮抑素的临床疗效与安全性。方法选取进展期卵巢癌患者69例,采用随机数字表法分为对照组34例和观察组35例。两组患者均在进展期卵巢癌细胞减灭术后接受TP方案化疗,共4个疗程。在此基础上,观察组患者在进展期卵巢癌细胞减灭术后第1、8天将60mg/m2重组人血管内皮抑素与0.9%氯化钠溶液混合至3 000ml,进行腹腔热灌注治疗;对照组患者接受腹腔热灌注等量0.9%氯化钠溶液治疗。化疗4个疗程结束后,比较两组患者血管内皮生长因子(VEGF)水平、治疗有效率、不良反应发生情况和2年生存率。结果4个疗程结束后,观察组患者血清VEGF水平低于对照组,且两组患者血清VEGF水平均较治疗前降低,差异均有统计学意义(均P<0.05)。观察组患者治疗有效率为51.43%,高于对照组的26.47%,差异有统计学意义(P<0.05)。两组患者心血管毒性、骨髓抑制、胃肠道反应、脱发、肌肉或关节酸痛等不良反应发生情况比较差异均无统计学意义(均P>0.05)。观察组患者2年生存率为82.86%,高于对照组患者的61.76%,差异有统计学意义(P<0.05)。结论在TP方案基础上,给予进展期卵巢癌术后患者腹腔热灌注重组人血管内皮抑素治疗,能够有效抑制肿瘤生长,降低VEGF水平,提高近期疗效和生存率,且不良反应发生率并未升高,具有较高的安全性和较好的临床效果。
Objective To assess the efficacy of rh-endostatin intraperitoneal hyperthermic therapy(IPHC)combined with TP regime chemotherapy in postoperative patients with advanced ovarian cancer.Methods Sixty nine cases of advanced ovarian cancer patients were enrolled in the study.Patients were divided into study group and control group randomly,both groups were given with TP regimen chemotherapy after ovarian cancer cell ablation.In the study group,patients received 60mg/m2 rh-endostatin in 3 000ml 0.9%sodium chloride solution for IPHC at d1 and d8,while patients in control group received equal amount of normal saline for intraperitoneal hyperthermic therapy.After 4 courses of treatment,the levels of vascular endothelial growth factor(VEGF),the effective rate,the incidence of adverse reactions and the 2-year survival rate were compared between the two groups.Results The level of VEGF in both groups was lower than that before treatment,while the level of VEGF after treatment in the study group was lower than that in the control group(all P<0.05).The effective rate of the study group was 51.43%,which was higher than that of the control group(26.47%,P<0.05).There was no significant difference in cardiovascular toxicity,bone marrow suppression,gastrointestinal reaction,alopecia,muscle or joint pain between the two groups(all P>0.05).The 2-year survival rate of the control group was 61.76%,which was lower than that of the study group(82.86%,P<0.05).Conclusion On the basis of TP regimen,rh-endostatin IPHC can reduce the VEGF level and effectively inhibit tumor growth with low adverse reaction rate and high safety in patients with advanced ovarian cancer.
作者
王小艳
崔洪银
俞丁丁
WANG Xiaoyan;CUI Hongyin;YU Dingding(Department of Obstetrics,the First People’s Hospital of Yuhang District,Hangzhou 311100,China)
出处
《浙江医学》
CAS
2019年第15期1629-1632,共4页
Zhejiang Medical Journal
关键词
重组人血管内皮抑素
卵巢癌
进展期
腹腔热灌注
Rh-endostatin
Ovarian cancer
Advanced stage
Intraperitoneal hyperthermic therapy
